Biohaven Pharmaceutical Holding Company Ltd. Stock

$15.46

0.83% yesterday

NYSE, Jun 13, 10:10 pm CET

ISIN

VGG111961055

Symbol

BHVN

Reports

Quarter | Annual

Index

NYSE Composite

Sector

Health

Industry

Pharmaceuticals

Overview Dividends Analysts Charts News Strategies

Biohaven Pharmaceutical Holding Company Ltd. Stock price

$15.46

-52.92 77.39% 5Y

NYSE, Closing price Fri, Jun 13 2025

-0.13 0.83%

ISIN

VGG111961055

Symbol

BHVN

Reports

Quarter | Annual

Index

NYSE Composite

Sector

Health

Industry

Pharmaceuticals

Key metrics

Market capitalization	$1.59b
Enterprise Value	$1.27b
P/E (TTM) P/E ratio	negative
EV/FCF (TTM) EV/FCF	negative
P/B ratio (TTM) P/B ratio	6.13
Revenue (TTM) Revenue	$0.00
EBIT (operating result TTM) EBIT	$-923.43m
Free Cash Flow (TTM) Free Cash Flow	$-649.01m
Cash position	$322.75m
EPS (TTM) EPS	$-8.71
P/E forward	negative
P/S forward	204.20
EV/Sales forward	162.80
Short interest	11.97%

As a Free StocksGuide user, you can view scores for all 6,847 stocks worldwide.

Get Started for Free Today

Biohaven Pharmaceutical Holding Company Ltd. Stock Analysis

Unlock Scores for Free

??

15 Analysts have issued a Biohaven Pharmaceutical Holding Company Ltd. forecast:

14x Buy

93%

More details on Analyst Estimates Including Price Targets

15 Analysts have issued a Biohaven Pharmaceutical Holding Company Ltd. forecast:

Buy

93%

Hold

Analyst Estimates with Stock Price Targets

Financial data from Biohaven Pharmaceutical Holding Company Ltd.

Income Statement P&L | Balance Sheet | Cash Flow

Quarter TTM Annually

Mar '25		+/- %
Revenue	- -	- 100%
- Direct Costs	- -	- -
Gross Profit	- -	- -
- Selling and Administrative Expenses	96 96	27% 27% -
- Research and Development Expense	827 827	78% 78% -
EBITDA	-915 -915	71% 71% -
- Depreciation and Amortization	8.66 8.66	29% 29% -
EBIT (Operating Income) EBIT	-923 -923	71% 71% -
Net Profit	-889 -889	72% 72% -

In millions USD.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Subscribe Now

Biohaven Pharmaceutical Holding Company Ltd. Stock News

Neutral

GlobeNewsWire

●

3 days ago

Bexorg Announces Research Collaboration with Biohaven Leveraging Its Novel AI-Driven Whole-Brain Discovery Platform to Enhance CNS Drug Development

NEW HAVEN, Conn., June 10, 2025 (GLOBE NEWSWIRE) -- Bexorg, Inc., a pioneering techbio company working to decode the human brain and advance new therapies for central nervous system (CNS) disorders, today announced a multi-program research collaboration with Biohaven Ltd.

Neutral

PRNewsWire

●

16 days ago

Biohaven Enrolls First Patient into Phase 2/3 Trial in Early Parkinson's Disease, Targeting Neuroinflammation with Novel Brain-Penetrant TYK2/JAK1 Inhibitor

BHV-8000 is a first-in-clinic, brain-penetrant, and selective inhibitor of TYK2 and JAK1 kinases — a novel investigational therapy with the potential to treat the neuroinflammation and immune dysregulation that drives disease progression in Parkinson's disease (PD) Currently, there are no approved disease-modifying therapies for the more than 10 million people living with PD NEW HAVEN, Conn. , ...

Neutral

PRNewsWire

●

16 days ago

Biohaven Highlights Innovation and Advancement Across MoDE and TRAP Degrader Platform at R&D Day, Announcing Positive TRAP Degrader Data Achieving > 80% Sustained Reductions in Galactose-Deficient IgA1 (Gd-IgA1) with Potential First-in-Class BHV-1400 for IgA Nephropathy (IgAN)

Optimized subcutaneous (SC) administration of BHV-1400 achieved rapid, deep, selective, and sustained lowering of Gd-IgA1, differentiating Biohaven's leading TRAP degrader for IgAN from the complement and BLyS/APRIL inhibitor competition. Up to 81% reduction of Gd-IgA1 was observed, with reductions from baseline sustained for weeks after a single SC dose administration.

More Biohaven Pharmaceutical Holding Company Ltd. News

Company Profile

Biohaven Pharmaceutical Holding Co. Ltd. is a clinical-stage biopharmaceutical company, which engages in the research and development of late-stage product candidates targeting neurological diseases, including rare disorders. It focuses on a pipeline of product candidates that represent mechanistic platforms, calcitonin gene-related peptide receptor antagonists, and glutamate modulators. The company was founded in September 2013 and is headquartered in New Haven, CT.

Head office	Virgin Islands, British
CEO	Vladimir Coric
Employees	256
Founded	2022
Website	www.biohaven.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now